Oncternal Therapeutics, Inc. announced the receipt of a 'Study May Proceed' letter from the U.S. Food and Drug Administration (FDA), 30 days after submitting its Investigational New Drug (IND) application for a Phase 1/2 dose escalation study of ONCT-808, an autologous chimeric antigen receptor (CAR) T therapy targeting ROR1, in patients with aggressive B cell non-Hodgkin's lymphoma (B NHL), including those who have failed previous CD19 CAR T treatment.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
8.5 USD | -3.19% | -9.67% | -20.74% |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-20.74% | 24.57M | |
+46.19% | 55.7B | |
-6.14% | 39.57B | |
+39.19% | 39.91B | |
-6.65% | 28.16B | |
+12.33% | 26.3B | |
-21.78% | 18.94B | |
-0.35% | 12.12B | |
+24.18% | 12.12B | |
+28.38% | 12.17B |
- Stock Market
- Equities
- ONCT Stock
- News Oncternal Therapeutics, Inc.
- Oncternal Therapeutics Receives IND Clearance for ONCT-808, Its Autologous Car T Product Candidate Targeting Ror1 for the Treatment of Aggressive B Cell Lymphoma